Abstract. Tumor angiogenesis is an important factor which precipitates recurrence and metastasis of colorectal cancer (CRC). Angiogenesis is also a significant feature which accompanies invasion and metastasis of CRC. Tumor hypoxia activates hypoxia inducible factor (HIF), which promotes angiogenesi
Li-hong Zhou,Hua Sui,Ting Wang,Ru Jia,Zhaozhou Zhang,Fu Jie,Yuanyuan Feng,Ningning Liu,Ji Qing,YAN WANG,Bimeng Zhang,Li Qi,Li Yan
2020-01-01
Abstract:Tumor angiogenesis is an important factor which precipitates recurrence and metastasis of colorectal cancer (CRC). Angiogenesis is also a significant feature which accompanies invasion and metastasis of CRC. Tumor hypoxia activates hypoxia inducible factor (HIF), which promotes angiogenesis in CRC. HIF significantly promotes cell proliferation and angiogenesis in CRC, facilitating invasion and metastasis. Tanshinone IIA (Tan IIA) has been revealed to effectively inhibit angiogenesis in CRC, although the underlying mechanism remains to be determined. The aim of the present study was to determine the effects of HIF-1α on hypoxia induced angiogenesis in CRC cells, the effects of Tan IIA on the expression of pro-angiogenic factors in CRC cells, and on human umbilical vein endothelial cell (HUVEC) tube formation in normal and hypoxic conditions. The results of the present study revealed that Tan IIA not only decreased HIF-1α expression and inhibited the secretion level of vascular endothelial growth factor and basic fibroblast growth factor, but also efficiently decreased proliferation, tube formation and metastasis of HUVECs. The results highlight the potential of Tan IIA-mediated targeting of HIF-1α as a potential therapeutic option for treatment of patients with CRC. Introduction Colorectal cancer (CRC) is one of the most frequently observed substantive malignancies in clinical operations. CRC is the third most common cancer among male patients and the second most common cancer among female patients worldwide. The mortality rate among male patients is the fourth highest and for female patients it is the third highest among all types of cancer worldwide (1). The incidence and mortality rates have been increasing annually over the past two decades. Research on postoperative prevention and treatment of CRC has resulted in improvements to treatments; however, the 5-year survival rate has not improved significantly. One of the major challenges in treating CRC is tumor neovascularization which results in invasion and metastasis of CRC to other organ tissues (2,3). Tumor angiogenesis is one of the primary means by which CRC invades and metastasizes, and frequently accompanies invasion and metastasis of CRC. Hypoxia is a frequently observed pathological state in solid tumors. Rapid proliferation of CRC cells results in local tumor tissues becoming hypoxic, and activating the core hypoxia response factor, upregulation of hypoxia inducible factor 1α (HIF-1α). HIF-1α is a basic regulatory factor of tumor angiogenesis during hypoxic conditions. It is composed of a heterodimer of α and β subunits. The hypoxic microenvironment results in activation of HIF-1α in tumor cells, which in turn upregulates the expression of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) (4,5) and basic fibroblast growth factor (bFGF) (6), which increase vascularization in the solid tumor, and participate in multiple aspects of tumor formation. Therefore, HIF-1α expression levels in tissues and cells can be used as a key indicator when monitoring tumor neovascularization (7) and HIF-1α-based antineoplastic drug filtering (8). It is also a key indicator used to evaluate the effectiveness of clinical tumor neovascularization treatments (9). Tanshinone IIA (Tan IIA) is the active ingredient of Salvia, a traditional Chinese medicine, which inhibit growths, induces apoptosis and reverses multidrug resistance in various types of human cancer cells. However, there are relatively fewer studies investigating the effects of Tan IIA on tumor neovascularizaTanshinone IIA reduces secretion of pro‐angiogenic factors and inhibits angiogenesis in human colorectal cancer LIHONG ZHOU1,2*, HUA SUI2*, TING WANG2, RU JIA2, ZHAOZHOU ZHANG2, JIE FU2, YUANYUAN FENG2, NINGNING LIU2, QING JI2, YAN WANG2, BIMENG ZHANG3, QI LI2 and YAN LI1 1Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071; 2Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203; 3Department of Acupuncture, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 201620, P.R. China Received January 14, 2019; Accepted January 24, 2020 DOI: 10.3892/or.2020.7498 Correspondence to: Dr Yan Li, Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 274 Middle Zhijiang Road, Shanghai 200071, P.R. China E-mail: 18916767226@163.com Dr Qi Li, Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai 201203, P.R. China E-mail: lzwf@hotmail.com *Contributed equally